| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 61.57 | -0.13 (-0.21%) | 12.87 - 63.72 | 1.8 million (Above Avg) |
Market data as of 4:00PM 05/17/13. Quotes are delayed by at least 15 min.
| Open | 61.73 |
|---|---|
| Previous Close | 61.70 |
| Day's Range | 58.83 - 62.69 |
| Market Cap | 1.8B |
| Avg Volume (10 Day) | 929.4K |
| Price/Earnings (Trailing 12 Mo.) | -- |
| Earnings Per Share (Trailing 12 Mo.) | -2.74 |
| Dividend Yield | No Dividend |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Fail |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Neutral |
| Increased shareholder value? | Neutral |
| Consistently increased owner earnings? | Fail |
| Sells at 25% discount to intrinsic value? | Fail |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Neutral |
|---|---|
| Room to increase dividends? | Fail |
| Increased earnings over time? | Neutral |
| Borrows within reasonable limits? | Pass |
| Stock is undervalued? | Fail |
| Have investors caught on? | Fail |
| Has support of institutional investors? | Pass |
| Has sufficient liquidity? | Pass |
No news headlines available for AEGR
| AEGR | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | -- | |
| Net Income Growth (1yr) | -- | |
| Total Debt/Equity | 0.08 | |
| LT Debt/Equity | 0.05 | |
| Earnings Yield | -- | |
| Price/Sales | 1441.42 |
| Company | Last | Change |
|---|---|---|
| Impax Laboratories Inc | 18.42 | -1.18% |
| Pacira Pharmaceuticals Inc | 29.44 | +0.93% |
| BioScrip Inc | 13.29 | -0.45% |
| Neurocrine Biosciences Inc | 11.75 | -2.00% |
| Keryx Biopharmaceuticals Inc | 8.04 | +0.50% |
Data is delayed by at least 15 min.